Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
about
Identification of semaphorin E as a non-MDR drug resistance gene of human cancersRole of copper transporters in platinum resistanceChemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of actionCombination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cellsExosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatinMetallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cellsCopper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubulesApoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulinEndocytic recycling compartments altered in cisplatin-resistant cancer cells.Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitroSelective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.Recently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment.Modulation of cis-diamminedichloroplatinum(II) resistance: a review.Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenograftsEffect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin.Cisplatin-DNA damage recognition proteins in human tumour extracts.In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line.Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexesTamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo.Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changesInduction of hepatic metallothionein I in tumour-bearing mice.Pressure tuning infrared spectroscopic study of cisplatin-induced structural changes in a phosphatidylserine model membrane.Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression.Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II).Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.Tissue platinum concentration and tumor response in non-small-cell lung cancerPredicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography
P2860
Q24315145-C4E62B52-54DE-499F-BBB0-B680A9EA9384Q26767028-3ADDA217-1511-46CF-B593-403865A3DC13Q27693179-CD2D6617-84BF-411C-B7A0-E295AF36B1B5Q28368394-C94A04AC-A5CA-45F1-9601-C04CE3D8892DQ28539631-5BE2BABA-77E8-46D8-9D42-FF5524520E76Q30494430-4439E63F-5EB3-4C2D-A1F8-D5C81D84BF9BQ33630801-D51EBC8F-4066-461E-A08D-959B55E855DFQ33822719-F24FFD05-5F74-4492-9518-3521625DA77EQ33875938-30062255-1803-4552-8BD9-E6FF705837BBQ34114078-70601E88-0316-4A80-A5D8-809261CB4982Q34212131-EAB834A6-3A62-4C91-9835-D387C5C7D03FQ34406800-26C62379-699A-41C1-BB35-2EA03471D383Q34458507-A4485EBC-F5AD-45C5-BAB7-01555173FCD2Q34510663-67C7B472-2039-40D5-9FC8-2C10A1647CC9Q34625095-6228E72F-6E43-40CD-9FA4-30A642FB3831Q34625375-981CDCE0-FFD9-4047-88DC-235F2A64FC29Q35553372-F0BD95F8-1BA0-484B-9709-E2C62C88096BQ35578368-60943789-0107-4249-A0E1-2D6D376B4D6BQ35707858-195FAB33-E56F-4B1E-AC2E-7F6A8B401F8AQ35932794-572F2BF1-1421-47FE-BF04-133857DBFCEDQ35975934-EF8E91CA-2EB8-429D-ABD4-A3348C7282FAQ35976413-43C83F9E-1827-43BB-BD3D-AC9D2D76E235Q35976534-504271C5-E136-4808-97F9-342AE54265F8Q35977240-A9383223-0656-4669-94EF-9F5ACFDF811DQ35977736-3F6D1F6A-6B82-434C-9D0C-AEEE8A7031D1Q35978030-A9900B12-4E78-460A-8EB7-862AC4EC3F1AQ35993429-9245704F-2011-4A4C-88EC-05894D9EE285Q35994616-EF04725F-17BF-4F4E-A883-3230720F5D22Q35994695-2298A107-799D-423C-8A04-726EE876479EQ36079645-E5777E62-837D-4478-BADA-B565E5AA3705Q36080620-4C635899-9C3F-4819-9B62-3CF82F10E849Q36080744-BB78ED14-690D-4C76-9234-134FC67B0915Q36080752-D7E962DF-6590-4C84-BDC3-AAFE33DBF37BQ36081734-B9506E46-9523-48CD-B149-7C8A03D09366Q36134626-03480364-4153-4663-BB18-C0550E91A265Q36135705-84D3F75B-53A3-4D5B-BA0D-562D6C499D96Q36135855-40EC2CD9-1EC5-4FE5-839A-087A7FEC818EQ36136501-01730B2A-CD49-4692-9CB3-3A9D0D34D9CFQ36222930-E3D05116-2A6F-4228-AB9C-E0EE34831CE7Q36292392-F3B73B40-7E03-4F2C-BDC1-EA1A1E01A73C
P2860
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@en
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@nl
type
label
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@en
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@nl
prefLabel
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@en
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@nl
P1476
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.
@en
P2093
P577
1990-02-01T00:00:00Z